These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
530 related articles for article (PubMed ID: 19447220)
1. Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. Mazzanti R; Platini F; Bottini C; Fantappiè O; Solazzo M; Tessitore L Biochem Pharmacol; 2009 Jul; 78(1):21-32. PubMed ID: 19447220 [TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Fantappiè O; Solazzo M; Lasagna N; Platini F; Tessitore L; Mazzanti R Cancer Res; 2007 May; 67(10):4915-23. PubMed ID: 17510421 [TBL] [Abstract][Full Text] [Related]
3. Id1 is down-regulated by hepatocyte growth factor via ERK-dependent and ERK-independent signaling pathways, leading to increased expression of p16INK4a in hepatoma cells. Ushio K; Hashimoto T; Kitamura N; Tanaka T Mol Cancer Res; 2009 Jul; 7(7):1179-88. PubMed ID: 19567783 [TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Zhang GS; Liu DS; Dai CW; Li RJ Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520 [TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Cui W; Yu CH; Hu KQ Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255 [TBL] [Abstract][Full Text] [Related]
6. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364 [TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Lasagna N; Fantappiè O; Solazzo M; Morbidelli L; Marchetti S; Cipriani G; Ziche M; Mazzanti R Cancer Res; 2006 Mar; 66(5):2673-82. PubMed ID: 16510587 [TBL] [Abstract][Full Text] [Related]
8. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760 [TBL] [Abstract][Full Text] [Related]
9. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Liu B; Shi ZL; Feng J; Tao HM Cell Biol Int; 2008 May; 32(5):494-501. PubMed ID: 18078766 [TBL] [Abstract][Full Text] [Related]
10. A chenodeoxycholic derivative, HS-1200, induces apoptosis and cell cycle modulation via Egr-1 gene expression control on human hepatoma cells. Park SE; Lee SW; Hossain MA; Kim MY; Kim MN; Ahn EY; Park YC; Suh H; Kim GY; Choi YH; Kim ND Cancer Lett; 2008 Oct; 270(1):77-86. PubMed ID: 18554781 [TBL] [Abstract][Full Text] [Related]
11. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230 [TBL] [Abstract][Full Text] [Related]
12. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Chen C; Chang YC; Liu CL; Liu TP; Chang KJ; Guo IC Endocr Relat Cancer; 2007 Jun; 14(2):513-29. PubMed ID: 17639064 [TBL] [Abstract][Full Text] [Related]
13. Attenuation of transforming growth factor beta-induced growth inhibition in human hepatocellular carcinoma cell lines by cyclin D1 overexpression. Jong HS; Lee HS; Kim TY; Im YH; Park JW; Kim NK; Bang YJ Biochem Biophys Res Commun; 2002 Mar; 292(2):383-9. PubMed ID: 11906173 [TBL] [Abstract][Full Text] [Related]
14. Expression of CD147 mediates tumor cells invasion and multidrug resistance in hepatocellular carcinoma. Jia L; Xu H; Zhao Y; Jiang L; Yu J; Zhang J Cancer Invest; 2008 Dec; 26(10):977-83. PubMed ID: 19093255 [TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Maier TJ; Schilling K; Schmidt R; Geisslinger G; Grösch S Biochem Pharmacol; 2004 Apr; 67(8):1469-78. PubMed ID: 15041464 [TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Kern MA; Haugg AM; Koch AF; Schilling T; Breuhahn K; Walczak H; Fleischer B; Trautwein C; Michalski C; Schulze-Bergkamen H; Friess H; Stremmel W; Krammer PH; Schirmacher P; Müller M Cancer Res; 2006 Jul; 66(14):7059-66. PubMed ID: 16849551 [TBL] [Abstract][Full Text] [Related]
17. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest. Ralstin MC; Gage EA; Yip-Schneider MT; Klein PJ; Wiebke EA; Schmidt CM Mol Cancer Res; 2006 Jun; 4(6):387-99. PubMed ID: 16778086 [TBL] [Abstract][Full Text] [Related]
18. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Zheng LH; Bao YL; Wu Y; Yu CL; Meng X; Li YX Cancer Lett; 2008 Dec; 272(1):102-9. PubMed ID: 18703276 [TBL] [Abstract][Full Text] [Related]
19. Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro. Lai PB; Chi TY; Chen GG Apoptosis; 2007 Feb; 12(2):387-93. PubMed ID: 17191126 [TBL] [Abstract][Full Text] [Related]
20. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Baiz D; Pozzato G; Dapas B; Farra R; Scaggiante B; Grassi M; Uxa L; Giansante C; Zennaro C; Guarnieri G; Grassi G Biochimie; 2009 Mar; 91(3):373-82. PubMed ID: 19041685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]